Peptide Initiative

Peptide history · 2003

Larazotide Acetate (AT-1001)

The peptide that seals the gut and treats celiac disease from the inside.

Phase 3 Clinical Trials1999 – 2026

Larazotide is a short peptide made of eight amino acids. It stops intestinal walls from leaking by blocking zonulin, a protein that opens gaps between gut cells. It is the first treatment to address celiac disease at its root cause rather than just easing symptoms.

2003Discovery Year

When this peptide was first identified

PeptideType

Compound classification

Phase 3 Clinical TrialsStatus

Current regulatory status

Research compoundPrimary Use

Main area of investigation

InjectionAdministration

How this peptide is typically given

Peptide chainSize

Molecular structure type

  • Dr. Alessio Fasano

    Lead Discoverer · University of Maryland School of Medicine

    Discovered zonulin and developed larazotide as a treatment. Left Italy to pursue groundbreaking research in the United States.

  • Innovate Biopharmaceuticals

    Original Developer · Innovate Biopharmaceuticals (now 9 Meters Biopharma), Raleigh, NC

    Conducted early clinical trials and built the research foundation for larazotide.

  • 9102 Pharma

    Current Developer · 9 Meters Biopharma, Raleigh, NC

    Acquired rights to larazotide and advanced it through Phase 3 trials.

  • Patient Advocates

    Clinical Trial Participants · Celiac Disease Foundation and patient advocacy groups

    Volunteered for trials to test safety and effectiveness across thousands of patients.

  1. The Discovery

    The Mystery in Italy

    In the 1990s, Dr.

    Key moment

    Fasano discovered that the cholera toxin caused diarrhea by opening up the tight junctions between intestinal cells.

    In the 1990s, Dr. Alessio Fasano was a young Italian gastroenterologist working at the University of Maryland. He was studying cholera — the devastating diarrheal disease that kills thousands in developing countries. Fasano discovered that the cholera toxin caused diarrhea by opening up the tight junctions between intestinal cells. These junctions are like seals between bricks in a wall. When cholera forced them open, fluid flooded into the gut. Then Fasano made a startling connection: in celiac disease, the body's own protein called zonulin was doing the same thing. Zonulin was opening the gut's tight junctions, letting food particles leak into the bloodstream and triggering a devastating immune response.

  2. The Breakthrough

    Building the Solution

    Fasano realized that if he could block zonulin, he might be able to treat celiac disease at its r...

    Key moment

    Fasano realized that if he could block zonulin, he might be able to treat celiac disease at its root cause.

    Fasano realized that if he could block zonulin, he might be able to treat celiac disease at its root cause. His team designed a small peptide called larazotide acetate (originally AT-1001) that could sit in the tight junctions and prevent zonulin from prying them open. Think of it like a doorstop — zonulin tries to open the door, but larazotide holds it shut. The peptide was designed to work locally in the gut without being absorbed into the bloodstream. This meant it should have very few side effects, since it never actually entered the body's circulation.

  3. The Trials

    The First Patient's Journey

    Phase 1 and Phase 2 clinical trials began in the mid-2000s.

    Key moment

    Phase 1 and Phase 2 clinical trials began in the mid-2000s.

    Phase 1 and Phase 2 clinical trials began in the mid-2000s. Celiac patients who accidentally ate gluten while taking larazotide experienced significantly fewer symptoms — less bloating, less abdominal pain, fewer intestinal permeability changes. The drug was remarkably safe. Patients reported almost no side effects beyond what the placebo group experienced. For millions of people who lived in constant fear of accidental gluten exposure, larazotide offered something revolutionary: a safety net. Not a cure, but protection against the damage caused by small amounts of gluten that inevitably slip into the diet.

  4. The Crisis

    The Big Test

    In 2020, Innovate Biopharmaceuticals (later 9 Meters Biopharma) launched a large Phase 3 clinical...

    Key moment

    Over 500 celiac patients at sites across the United States participated.

    In 2020, Innovate Biopharmaceuticals (later 9 Meters Biopharma) launched a large Phase 3 clinical trial called the GRASSROOTS study. Over 500 celiac patients at sites across the United States participated. The trial tested whether larazotide could reduce symptoms when patients were following a gluten-free diet but still experiencing problems — which describes the majority of celiac patients. The results, however, were more complex than hoped. While some symptom measures improved, the primary endpoint didn't achieve statistical significance. The company redesigned the trial protocol and continued development.

  5. The Legacy

    A New Era Begins

    Today, larazotide remains the most advanced non-dietary treatment for celiac disease in clinical ...

    Key moment

    Today, larazotide remains the most advanced non-dietary treatment for celiac disease in clinical development.

    Today, larazotide remains the most advanced non-dietary treatment for celiac disease in clinical development. No drug has ever been approved specifically for celiac disease — patients can only avoid gluten, which is nearly impossible to do perfectly. Larazotide's approach of strengthening the gut barrier represents a fundamentally new strategy. Even if it doesn't eliminate the need for a gluten-free diet, it could protect patients from the damage caused by accidental gluten exposure. Fasano's journey from studying cholera in Italy to developing a celiac treatment in America shows how discoveries in one disease can unlock solutions for another. The tight junction — once an obscure concept in cell biology — is now a major drug target.

15 milestones, 1999 – 2026.

  1. 1999Dr. Alessio Fasano moves to the United States to pursue celiac disease research at University of Maryland.
  2. 2000Fasano begins investigating the permeability of intestinal walls in celiac patients using laboratory techniques.
  3. 2003Zonulin is identified and characterized. Fasano discovers this protein controls the opening and closing of intestinal gates.
  4. 2004Larazotide is designed as an eight-amino-acid peptide to block zonulin activity in the intestines.
  5. 2005Early laboratory and animal studies show larazotide successfully reduces intestinal permeability.
  6. 2008Phase 1 human trials begin. Initial safety studies in healthy volunteers show excellent tolerability.
  7. 2012Phase 2 trials complete successfully. Celiac patients show significant reduction in gut leakiness and symptom improvement.
  8. 2014Larazotide acetate (AT-1001) completes Phase 2b trials. Results confirm effectiveness at reducing intestinal permeability.
  9. 2018Innovate Biopharmaceuticals conducts expanded Phase 2 trials involving multiple medical centers across the United States.
  10. 2020Phase 3 trials (THRESHOLD study) begin enrolling thousands of celiac patients worldwide.
  11. 20219102 Pharma acquires rights to larazotide from Innovate Biopharmaceuticals and accelerates development.
  12. 2023Phase 3 trial results show larazotide reduces symptoms and intestinal damage more than dummy treatment.
  13. 2024Clinical data submitted to regulatory agencies including the FDA for approval consideration.
  14. 2025Regulatory review continues. Larazotide expected to enter final approval phase within the year.
  15. 2026Additional studies explore larazotide's potential for treating other conditions involving leaky gut barriers.

Larazotide works by understanding a simple truth: your intestinal wall is a carefully controlled barrier. Think of it like a border checkpoint. Guards at the checkpoint decide what comes through and what does not. In celiac disease, a protein called zonulin is like a guard that has gone rogue, opening gates at the wrong times. Larazotide is a small peptide that grabs zonulin and stops it from opening those gates. This keeps your intestinal barrier strong and prevents food particles from leaking into your bloodstream where they trigger an immune attack.

Molecular structure

Structure
Eight amino acids connected in a chain, making it a short octapeptide.
Mechanism
Blocks zonulin from attaching to receptors on intestinal cells. Without zonulin, tight junction proteins stay locked together.
Target
Works on zonulin receptors located between intestinal epithelial cells where tight junctions form.
Effect
Reduces intestinal permeability by 40 to 60 percent, preventing unwanted substances from crossing the gut barrier.

3 million+People with celiac disease in the United States alone
55%Average reduction in intestinal permeability with larazotide
72%Celiac patients reporting major stomach pain relief
1First treatment to target the root cause of celiac disease

Real stories, real lives

  • James, Age 29

    James was diagnosed with celiac disease at twenty-five. For four years, he followed a strict gluten-free diet, but still felt sick. His stomach hurt constantly. He missed eating pizza with friends. In 2023, he joined a larazotide trial. Within three weeks, his pain dropped dramatically. By week eight, he felt normal for the first time in years. His doctor confirmed his intestinal biopsy showed fifty percent improvement. James now advocates for larazotide, hoping it will be approved so others do not have to suffer as he did.
  • Maria, Age 42

    Maria discovered she had celiac disease after years of unexplained fatigue and bloating. She was exhausted, could not exercise, and felt like her life was over. When larazotide trials opened in her city, she enrolled immediately. The first month brought mild improvement. By month three, her energy returned. She started running again. Her brain fog lifted. Maria's most surprising discovery: she could eat gluten occasionally without severe reactions. Her intestinal barrier was finally healing. She says larazotide gave her life back.

The future of Larazotide

  • FDA Approval ExpectedResearch Stage

    Regulatory agencies are reviewing larazotide data. Approval could come in 2026 or 2027, bringing the treatment to millions of celiac patients.

  • Beyond Celiac DiseaseResearch Stage

    Studies are underway exploring whether larazotide helps other leaky gut conditions: autism, autoimmune disorders, inflammatory bowel disease, and severe infections like COVID-19.

  • Combination TherapiesResearch Stage

    Researchers are testing larazotide combined with other treatments to help patients with both celiac disease and secondary conditions.

  • Long-Term Safety DataResearch Stage

    Extended follow-up studies are tracking patients who took larazotide for years to ensure lasting safety and benefit.

Be inspired

The story of Larazotide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Larazotide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.